Zentalis Pharmaceuticals
https://www.zentalis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zentalis Pharmaceuticals
Five Clinical Trial Misses Of 2022
Drug makers have sought to branch into new frontiers of drug development in areas like cancers and neurology, but not all of them have been success stories. Here, Scrip looks at some of the more notable clinical trial misses of last year.
Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
Finance Watch: A Summer Slowdown? Not For Venture Capital Mega-Rounds
Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.
Finance Watch: Five Biopharma IPOs Bring US Total To 60 In 2021
Public Company Edition: Almost halfway through the year, initial public offerings equal nearly three-quarters of the 2020 total. Also, Pardes is one of four new SPAC mergers; HUTCHMED launched an IPO in Hong Kong; and Zentalis, Theravance and BioXcel launched follow-on offerings.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Zeno Pharma, LLC
- Zeno Pharmaceuticals, Inc.
- Zentera Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice